• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ELI LILLY AND COMPANY HUMAPEN, UNKNOWN DEVICE FOR TREATMENT PURPOSES

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ELI LILLY AND COMPANY HUMAPEN, UNKNOWN DEVICE FOR TREATMENT PURPOSES Back to Search Results
Model Number UNKNOWN
Device Problem Use of Device Problem (1670)
Patient Problems Hearing Loss (1882); Hypoglycemia (1912)
Event Date 10/31/2018
Event Type  Injury  
Manufacturer Narrative
New, updated and corrected information is referenced within the update statements. Please refer to update statement dated (b)(6) 2018. No further follow-up is planned. Evaluation summary: a male patient reported that the dose window of his humapen ergo ii device was blurred. He experienced hypoglycemia. The device was not returned for investigation (batch unknown). Therefore, it could not be evaluated to confirm the complaint or presence of a malfunction. Malfunction unknown. All humapen ergo ii devices are assessed for injection screw travel at the end of the manufacturing process, thus ensuring device functionality and dose accuracy with high probability. The patient reported the device was used for more than 14 years. The core instructions for use states the device was designed to be used for up to 3 years after first use. There is evidence of improper use. The patient used the device beyond its approved use life. It is unknown if this is relevant to the complaint of dose window blurred or the event of hypoglycemia.
 
Event Description
Lilly case id: (b)(4). This report is associated with product complaint: (b)(4). This spontaneous case, reported by a consumer who contacted the company to report adverse events and a product complaint (pc), with additional information from initial reporter, concerned a male patient of unknown age and origin. Medical history included heart disease and his kidney was not good. Concomitant medications included acarbose for unspecified indication. The patient received an unspecified form of insulin lispro family (rdna origin) injections (humalog) from cartridge, via a reusable humapen (unknown device type) subcutaneously, for treatment of diabetes, beginning in 2004; dose and frequency were not provided. He also received insulin lispro protamine suspension 75%/ insulin lispro 25% (rdna origin) injections (humalog mix25) from cartridge via a reusable humapen (unknown device type), twice a day, 16 units in the morning and 8 units at night, subcutaneously, for the treatment of diabetes mellitus, beginning in 2004. Since an unknown date, after starting insulin lispro and lispro protamine suspension 75%/ insulin lispro 25%, his ears were not good; he became deaf. The event of deaf was considered as serious due to its medical significance. Since an unknown date, the dose window of his humapen was blurred and the soft touch was peeling off (associated pc (b)(4)/ lot number unknown). It was noted that the device was used 14 years. On an unspecified date in (b)(6) 2018, while on insulin lispro and lispro protamine suspension 75%/ insulin lispro 25% therapies, he was hospitalized due to hypoglycemia (no glucose values, units or reference range provided) for three days. Hospitalization details included admission and discharge dates, corrective treatment or laboratory examination findings were not provided. Information regarding corrective treatment and event outcome was not provided. Insulin lispro and lispro protamine suspension 75%/ insulin lispro 25% therapies were ongoing. The user of the device and his/her training status was not provided. The device model duration of use was not provided; suspect device duration of use was about 14 years. The suspect device was not returned to the manufacturer. The reporting consumer did not provide an assessment of relatedness between the hypoglycemia event and insulin lispro therapy and did not know if it was related to insulin lispro protamine suspension 75%/ insulin lispro 25% therapy. The reporting consumer did not know if the deafness event was related to any insulin therapy. The reporting consumer did not provide an assessment of relatedness between the events and suspect device. Update (b)(6) 2018: additional information was received from the reporting consumer on (b)(6) 2018. Added medical history, insulin lispro protamine suspension 75%/ insulin lispro 25% as co-suspect drug, added the serious event of hypoglycemia. Updated description as reported of the deafness event. Updated concomitant device to suspect device. Updated narrative accordingly. Update (b)(6) 2018: additional information was received from the responsible complaint person (rcp) on (b)(6) 2018. Pc reference number was processed; added device details (color and age, updated return status: not expected). Updated narrative accordingly. Update (b)(6) 2018: additional information received on (b)(6) 2018. No new medically significant information provided. No other changes made to the case. Edit (b)(6) 2018: upon review of information received on (b)(6) 2018, suspect drug was updated from insulin lispro to unspecified form of insulin lispro; hospitalization duration was removed, added three days as part of the event details. Updated narrative accordingly. Update (b)(6) 2018: additional information received on (b)(4) 2018 from the global product complaint database. Entered device specific safety summary (dsss). Updated the medwatch fields with device information, the european and canadian (eu/ca) device information, improper use and storage from no to yes, and device return status to not returned to manufacturer for pc (b)(4) associated with unknown lot of a humapen unknown device. Corresponding fields and narrative updated accordingly.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand NameHUMAPEN, UNKNOWN DEVICE
Type of DeviceFOR TREATMENT PURPOSES
Manufacturer (Section D)
ELI LILLY AND COMPANY
lilly corporate center
indianapolis IN 46285
Manufacturer (Section G)
PHILLIPS-MEDISIZE CORPORATION
415 red cedar street
medical device manufacturing
menomonie WI 54751
Manufacturer Contact
chris davis
lilly corporate center
indianapolis, IN 46285
3174334585
MDR Report Key8154877
MDR Text Key130049692
Report Number1819470-2018-00211
Device Sequence Number1
Product Code FMF
Combination Product (y/n)N
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type consumer,foreign
Type of Report Initial
Report Date 12/12/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received12/12/2018
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Other
Device Model NumberUNKNOWN
Was Device Available for Evaluation? No
Was the Report Sent to FDA?
Event Location No Information
Date Manufacturer Received11/12/2018
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Is the Device Single Use? No
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial

Patient Treatment Data
Date Received: 12/12/2018 Patient Sequence Number: 1
-
-